Close this search box.


Products & dossiers

We develop and manufacture our products after the careful selection and qualification of our partners. Product quality, supply chain stability and sustainability are of key importance to us. 

A full list of our dossiers available for in-licensing or in development can be found below.  

Dossier list

MoleculeOriginator brandIndicationStrengthsAdministrationMain sector¹Type of dossierDossier availabilityEU Data protection²Expected launch³
CaspofunginCancidas® by MerckAntifungal, systemic50 mg, 70 mgParenteralHospitalEU-CTDAvailableExpiredCommercial
AnidulafunginEcalta® by PfizerAntifungal, systemic100 mgParenteralHospitalEU-CTDAvailableExpiredCommercial
MicafunginMycamine® by AstellasAntifungal, systemic50 mg, 100 mgParenteralHospitalEU-CTDAvailableExpiredCommercial
RivaroxabanXarelto® by BayerAnticoagulant2.5 mg, 10 mg,
15 mg, 20 mg
OralRetailEU-CTDAvailableExpired04.2024 / 01.2026³
TicagrelorBrilique® by AstraZenecaAnticoagulant60 mg, 90 mgOralRetailEU-CTDAvailableExpired06.2025
Tafamidis MeglumineVyndaqel® by PfizerAmyloidosis20 mgOralMixedEU-CTDAvailableExpired11.2026
MacitentanOpsumit® by ActelionPulmonary hypertension10 mgOralMixedEU-CTDAvailableExpired12.2026
IsavuconazoleCresemba® by BasileaAntimycotic100 mgOralHospitalEU-CTDQ3’202510.2025⁴2026⁴
IsavuconazoleCresemba® by BasileaAntimycotic200 mgParenteralHospitalEU-CTDQ3’202510.2025⁴2026⁴
NusinersenSpinraza® by BiogenSpinal muscular atrophy12 mgParenteralEU-CTD
RisdiplamEvrisdy® by RocheSpinal muscular atrophy60 mgOralEU-CTD
Value added genericParenteralEU-CTD


¹Main sector is based on average IQVIA sales distribution by Standard Units in Europe

²Expected launch date applies for market entry of generic products in major European countries. Please check specific patent situation in any particular country of interest

³04.2024 referring to 2.5mg and 01.2026 to the rest of the presentations. Legal proceedings ongoing in several countries.

⁴High probability of pediatric extension to 10.2027, taking the launch to 2028.

For further information, please contact: moc.eimehctcelesobfsctd@gnisnecil.amrahp

Disclaimer: None of the products will be offered for sale or supply to countries in which they were affected by valid and effective patents in force.


Frank Buennig

VP Sales FDF & Nutrition

Interested in in-licensing?

If you are interested in in-licensing our dossiers, please contact us.

For information on our business model of the co-development of generics, click the button below.